Weight Watchers Med+ Establishes Access to GLP-1s Through Medicare GLP-1 Bridge Program

Rhea-AI Summary

Weight Watchers (NASDAQ:WW) announced that Weight Watchers Med+ will support Medicare beneficiaries accessing GLP-1 medications via the Medicare GLP-1 Bridge Program.

Eligible members with Medicare Part D can obtain select GLP-1 weight-loss drugs for $50 per month from July 1, 2026 through December 31, 2027, alongside Med+ clinical and behavioral support.

According to Weight Watchers, Med+ members on GLP-1s who engaged with the GLP-1 Success Program lost 29.1% more body weight at 12 months, and 73% reported that Med+ helps minimize medication side effects.

Positive

• Medicare GLP-1 Bridge access at $50 per month through 2027
• GLP-1 Success Program users lost 29.1% more body weight at 12 months
• 73% of Med+ members report Med+ helps minimize GLP-1 side effects

Negative

• None.

News Market Reaction – WW

-2.56%

-2.56% Session close to close

In the Jun 30 session, WW declined 2.56%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement broadens GLP‑1 access for Medicare members at $50 monthly, complementing earlier L...

Analysis

This announcement broadens GLP‑1 access for Medicare members at $50 monthly, complementing earlier LillyDirect and Ozempic pill initiatives. Prior news has mostly tracked sentiment, but elevated short positioning and execution on GLP‑1 programs remain key watchpoints.

Key Figures

Monthly GLP-1 cost: $50 per month Program start date: July 1, 2026 Program end date: December 31, 2027 +2 more

5 metrics

Monthly GLP-1 cost $50 per month Price for eligible GLP-1 medications under Medicare GLP-1 Bridge Program

Program start date July 1, 2026 Medicare GLP-1 Bridge Program effective date

Program end date December 31, 2027 Medicare GLP-1 Bridge Program expiration date

Additional weight loss 29.1% more body weight lost Med+ GLP-1 members engaging with GLP-1 Success Program at 12 months

Side-effect support 73% of Med+ members Reported Med+ helps minimize weight-loss medication side effects

Historical Context

5 past events · Latest: Jun 22 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 22	AHA study support	Positive	-4.1%	Backed American Heart Association study on real‑world weight and health outcomes.
Jun 16	UK partnership	Positive	+0.5%	Expanded CheqUp partnership integrating clinical and behavioral GLP‑1 support in the UK.
Jun 04	LillyDirect access	Positive	+7.0%	Joined LillyDirect platform to connect users to Med+ GLP‑1 program nationwide.
May 07	Q1 2026 earnings	Negative	-22.3%	Reported revenue growth but significant net loss and negative Adjusted EBITDA for Q1.
May 01	Ozempic pill access	Positive	+1.3%	Added FDA‑approved Ozempic pill to Med+ formulary for type 2 diabetes care.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

WW’s stock typically moves in line with news tone, though one recent positive collaboration headline drew a contrary negative reaction.

Key Terms

glp-1, medicare part d, prior authorizations

3 terms

glp-1 medical

"Medicare beneficiaries to GLP-1 medications covered by the Medicare Bridge Program."

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

medicare part d regulatory

"To qualify for the Medicare Bridge program, you must have Medicare Part D, meet clinical eligibility"

Medicare Part D is the U.S. federal program that helps people on Medicare pay for outpatient prescription drugs through private plans that negotiate prices and list covered medicines. For investors it matters because the program shapes how drugs are priced, which medicines get chosen by plans, and how much patients and insurers pay—similar to a large group discount card that influences sales, margins, and revenue predictability across drugmakers, insurers, pharmacies and pharmacy benefit managers.

prior authorizations regulatory

"navigate insurance coverage, paperwork, and prior authorizations so they can easily access care."

A prior authorization is a payer's advance approval required before a health plan will cover a specific medication, medical test, or procedure. For investors, it matters because these approvals affect how quickly and widely a treatment or service can be used—similar to needing a permit before opening a store—so delays or denials can reduce sales, change cost forecasts, and create uncertainty around revenue and market adoption.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Weight Watchers expands access for Med+ Medicare beneficiaries to GLP-1 medications covered by the Medicare Bridge Program.

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today announced that Weight Watchers Med+ will support Medicare members seeking access to GLP-1 medications under the Medicare GLP-1 Bridge Program.

Through the Medicare GLP-1 Bridge Program, eligible beneficiaries purchase GLP-1 medications for weight loss, including Zepbound^®, KwikPen^®, Foundayo^®, and Wegovy^® pen and pill, for $50 per month. The program will run from July 1, 2026 through December 31, 2027. In addition to prescribing medication when appropriate and managing care for these medications, Weight Watchers helps Med+ members navigate insurance coverage, paperwork, and prior authorizations so they can easily access care.

“For many people, weight loss is about health, mobility and being able to keep doing the things they love. At Weight Watchers, our goal is to make the process feel less overwhelming by helping members understand their options, access care and receive a GLP-1 prescription if they’re eligible, while also providing the support they need to live well on treatment,” said Scott Honken, PharmD, Chief Commercial Officer, Weight Watchers.

To qualify for the Medicare Bridge program, you must have Medicare Part D, meet clinical eligibility, and have a prescription for an eligible GLP-1 medication. This medication must be used alongside ongoing lifestyle changes, including nutrition and physical activity, to support weight loss and maintenance.

As Medicare beneficiaries consider GLP-1 treatment, Weight Watchers, a trusted brand for older adults on their health journey, offers comprehensive care beyond providing a prescription. Our Med + program blends clinical oversight with behavioral tools to deliver sustainable results. In addition to clinical care, members access nutrition support, medication tracking, refill reminders, and expert GLP-1 coaches through our integrated GLP-1 Success Program. Crucially for older adults, the program includes tailored strength-building guidance to preserve muscle mass and reduce the risk of frailty and falls.

Weight Watchers data show that Med+ members prescribed a GLP-1 medication who regularly engaged with the GLP-1 Success Program lost 29.1% more body weight on average at 12 months than those who did not engage in behavioral support.¹ In addition, 73% of Med+ members given the GLP-1 Success Program say that Weight Watchers Med+ helps minimize weight-loss medication side effects.²

ABOUT WEIGHT WATCHERS
Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.

For investor inquiries, please contact:
John Mills or Anna Kate Heller
WeightWatchers@icrinc.com

For media inquiries, please contact::
Melissa Garbayo
melissa.garbayo@ww.com

---

¹ Based on an internal analysis of 3,325 members who requested at least 1 GLP-1 medication refill through Weight Watchers Med+ and self-reported both a starting weight and weight at week 52. On average, members who logged in to the GLP-1 Success Program at least 4 days each week (n=376) lost 22.20% body weight, and members who never logged in to the app (n=2,949) lost 17.20% body weight in 52 weeks. Not a randomized, controlled clinical trial. Self-reported outcomes have not been independently verified. Individual results may vary.
² Based on an internal data analysis of 92,160 members who received a treatment plan, were prescribed an injectable GLP-1 medication through Weight Watchers, and recorded their starting weight and completed a weigh-in 4 weeks after starting their treatment plan.

FAQ

What is the Medicare GLP-1 Bridge Program offered through Weight Watchers Med+ (NASDAQ:WW)?

The Medicare GLP-1 Bridge Program lets eligible Medicare Part D beneficiaries buy select GLP-1 weight-loss medications for $50 per month. According to Weight Watchers, Med+ also provides prescribing, monitoring, and support tools to improve adherence, side-effect management, and long-term weight outcomes.

Which GLP-1 medications are available to WW Med+ members under the Medicare GLP-1 Bridge Program?

Eligible Med+ members can access GLP-1 medications including Zepbound, KwikPen, Foundayo, and Wegovy pen and pill for $50 per month. According to Weight Watchers, these drugs must be used with lifestyle changes such as nutrition improvements and increased physical activity.

What are the dates and cost of the Weight Watchers Medicare GLP-1 Bridge Program for WW stock investors to know?

The Medicare GLP-1 Bridge Program runs from July 1, 2026 through December 31, 2027, at $50 per month for eligible GLP-1 prescriptions. According to Weight Watchers, participants must have Medicare Part D, meet clinical criteria, and hold a qualifying GLP-1 prescription.

How effective is the WW Med+ GLP-1 Success Program in improving weight loss outcomes?

According to Weight Watchers, Med+ members on GLP-1s who regularly used the GLP-1 Success Program lost 29.1% more body weight at 12 months than those without behavioral support. The program combines clinical oversight, nutrition guidance, tracking tools, and expert GLP-1 coaching.

How does Weight Watchers Med+ help Medicare GLP-1 users manage side effects and safety?

Weight Watchers reports that 73% of Med+ members given the GLP-1 Success Program say Med+ helps minimize weight-loss medication side effects. The program includes clinical monitoring, medication tracking, refill reminders, and tailored strength-building guidance to preserve muscle and reduce frailty risks in older adults.

What are the eligibility requirements for Medicare beneficiaries to use GLP-1s with Weight Watchers Med+?

To qualify, members must have Medicare Part D, meet clinical eligibility criteria, and possess a prescription for an eligible GLP-1 medication. According to Weight Watchers, GLP-1 use must be combined with ongoing lifestyle changes such as nutrition and physical activity to support weight loss.